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Background: Bortezomib, a proteasome inhibitor and suberoylanilide hydroxamic acid (SAHA, also known as
Vorinostat), a histone deacetylase inhibitor, have been recognized as potent chemotherapeutic drugs. Bortezomib
and SAHA are FDA-approved for the treatment of cutaneous T cell lymphoma and multiple myeloma/mantle cell
lymphoma, respectively. Furthermore, the combination of the bortezomib and SAHA has been tested in a variety of
preclinical models and in clinical trials and may be ideal for the treatment of cancer. However, it remains unclear
how this treatment strategy affects the host immune response against tumors.
Results: Here, we used a well-defined E6/E7-expressing tumor model to examine how the immune system can
be motivated to act against tumor cells expressing tumor antigens. We demonstrate that the combination of
bortezomib and SAHA elicits potent antitumor effects in TC-1 tumor-bearing mice. Additionally, we are the first to
show that treatment with bortezomib and SAHA leads to tumor-specific immunity by rendering tumor cells more
susceptible to killing by antigen-specific CD8+ T cells than treatment with either drug alone.
Conclusions: The current study serves an important foundation for the future clinical application of both drugs for
the treatment of cervical cancer.
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Bortezomib is a proteasome inhibitor recognized as a
potent chemotherapeutic agent that is currently used
to treat relapsed multiple myeloma and mantle cell
lymphoma (for review see [1]). Bortezomib inhibits the
26S proteasome, which is a key regulator of intracellular
protein degradation. The downstream effects of bortezo-
mib include antitumor effects, which are the result of inhi-
biting tumor cell proliferation or promoting tumor cell
apoptosis [2]. Bortezomib-induced tumor cell apoptosis
may enhance the immunogenicity of tumor cells and pro-
vide an opportunity for generating tumor-specific immunity* Correspondence: chung2@jhmi.edu
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unless otherwise stated.[3]. We have previously elucidated the immune mechanism
of the antitumor effects of bortezomib in an ovarian cancer
model and found that bortezomib can be used to promote
the generation of antigen-specific CD8+ T cells [4]. It is im-
portant to further elucidate this mechanism, to determine
the utility of bortezomib as a therapeutic agent in additional
cancer models, and to identify other therapeutic agents that
may enhance the antitumor effects of bortezomib.
Histone deacetylase inhibitors (HDACi) have been iden-
tified as a class of drugs with anticancer properties that
can potentially be used in conjunction with bortezomib to
further enhance its cancer therapeutic effects. HDACi
inhibit an enzyme responsible for the deacetylation of
histones, and lead to the expression of suppressed genes
and regulation of abnormal cell growth [5]. HDACi may
also contribute to cancer control by histone-independentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proteins such as p53 [6] and heat shock protein-90 [7].
These mechanisms produce antitumor effects including
induced differentiation, cell growth arrest, and an increase
in apoptosis [8,9]. Furthermore, it has been shown that
treating cells with HDACi can lead to the upregulation of
MHC class I and II molecules [10]. This suggests that
tumor cells may become more susceptible to tumor-
specific CD8+ T cell immunotherapy following treatment
with an HDACi. One HDACi with therapeutic character-
istics is suberoylanilide hydroxamic acid (SAHA, also
known as Vorinostat), which is an FDA approved HDACi
used in the treatment of cutaneous T-cell lymphoma [11].
SAHA may be an ideal drug to use in combination with
bortezomib for the treatment of cancer.
Indeed, bortezomib and SAHA have previously been
used in combination in a xenogeneic model for the
treatment of cervical cancer [12]. This study found that
bortezomib-mediated cervical cancer cell apoptosis might
be facilitated by blocking E6-mediated proteasomal deg-
radation of p53. Furthermore, because HPV oncoprotein
E7 is known to interact with class I HDACs [13], Lin et al
examined the effects of SAHA with bortezomib on tumor
cell apoptosis. They found that the combination elicited
synergistic killing of HPV-expressing cervical cancer cell
lines and that the combination treatment diminished
tumor growth of HeLa xenografts more effectively than
either drug alone. Encouraged by these results, we took
the opportunity to examine a different aspect of the effects
of bortezomib and SAHA, namely, the host immune re-
sponse against tumor cells.
In the current study, we used a well-defined E6/E7-
expressing tumor model to examine how the immune
system can be motivated to act against tumor cells ex-
pressing tumor antigens. We demonstrate that the
combination of bortezomib and SAHA elicits potent
antitumor effects in TC-1 tumor-bearing mice. Further-
more, we are the first to show that treatment with borte-
zomib and SAHA leads to tumor-specific immunity by
rendering tumor cells more susceptible to killing by
antigen-specific CD8+ T cells than treatment with either
drug alone. Considering that both bortezomib and SAHA
are FDA-approved for the treatment of specific types of
cancer, this study has significant translational value.
Methods
Mice
Six- to 8-week-old female C57BL/6 mice were purchased
from the National Cancer Institute (Frederick, MD,
USA) and housed in the oncology animal facility of the
Johns Hopkins Hospital (Baltimore, MD, USA). All ani-
mal procedures were performed according to approved
protocols and in accordance with recommendations for
the proper use and care of laboratory animals.Reagents and cell lines
We have previously generated an E7-expressing tumori-
genic cell line, TC-1 [14], and a firefly luciferase-expressing
TC-1 cell line, TC-1-luc [15]. The H-2Db-restricted
HPV16 E7aa49-57 peptide, RAHYNIVTF, was synthe-
sized by Macromolecular Resources (Denver, CO) at a
purity of ≥80%. PerCP-Cy5.5-conjugated anti-mouse
CD3 (clone 17A2), anti-mouse CD45 (clone 30-F11),
FITC and PE-conjugated anti-mouse CD8a (clone 53.6.7),
FITC-conjugated rat anti-mouse CD4 (clone RM4-5),
FITC-conjugated rat anti-mouse IFN-γ (clone XMG1.2)
antibodies were purchased from BD Pharmingen (San
Diego, CA). PE-conjugated, HPV16 E749-57 peptide
loaded H-2Db tetramer was provided by NIAID tetramer
core facility (Atlanta, GA). Commercially available borte-
zomib (PS341; Millennium Pharmaceuticals) was reconsti-
tuted according to the manufacturer’s instructions and
diluted in 0.9% saline before in vivo administration. Suber-
oylanilide hydroxamic acid (SAHA, LC Laboratories) was
dissolved in DMSO and then diluted in 2-Hydroxypropyl-
β-cyclodextrin solution before each injection.
Cell viability assay
To determine the viability of TC-1 cells after bortezomib
and SAHA treatment, 3-(4,5-dimethyl-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner
salt (MTS, Promega) assay was performed. Briefly, TC-1
cells were plated in 96-well plates at a density of 1 × 103
cells/well and incubated at 37°C in the presence of 5%
CO2 for 12 hours. The cells were then treated with various
concentrations of bortezomib or SAHA for 48 hours,
respectively. At the end of the treatment period, MTS re-
agent was added to each well, and the plate was incubated
for 4 hours at 37°C in the dark. After incubation, the ab-
sorbance was measured at 490 nm using the VERSA Max
Microplate Reader. Data from three independent experi-
ments were analyzed and normalized to the absorbance of
wells containing media only (0%) and untreated cells
(100%). The IC50 values were calculated from sigmoidal
dose-response curves using MS Excel software. As shown
in Additional file 1: Figure S1, the IC50 for bortezomib in
TC-1 cells is 7.1 nM and that for SAHA is 25.7 μM.
In vivo treatment experiments
C57BL/6 mice were inoculated subcutaneously with 3 × 104
TC-1 cells/per mouse on day 0. The tumor-bearing mice
were divided into four groups (5 per group) based on the
treatment regimens: control (2-Hydroxypropyl-β-cyclodex-
trin solution only), bortezomib only, SAHA only, both bor-
tezomib and SAHA. For the administration of bortezomib,
1 mg/kg of bortezomib was injected intraperitoneally on
days 5, 8, 11, and 14 after tumor inoculation. For the SAHA
administration, 30 mg/kg of SAHA was injected inraperi-
toneally into tumor-bearing mice daily from day 5 to day
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vehicle alone using the same schedule as SAHA treatment.
Tumor measurement
Tumor size was monitored by measuring the longest
dimension (length) and shortest dimension (width)
using dial calipers at 3-day intervals. Tumor volume
was calculated by the following formula: tumor diam-
eter = 0.5 × (length + width).
Preparation of single-cell suspensions from TC-1 tumors
Four days after the last treatment, TC-1 tumors were
resected from mouse, placed in RPMI-1640 medium
containing 100U/ml penicillin and 100 μg/ml strepto-
mycin and washed with PBS. The solid tumors were
then minced into 1- to 2-mm pieces and immersed in
serum-free RPMI-1640 medium containing 0.05 mg/ml
collagenase I, 0.05 mg/ml collagenase IV, 0.025 mg/ml
hyaluronidase IV, 0.25 mg/ml DNase I, 100 U/ml penicil-
lin, and 100 μg/ml streptomycin and incubated at 37°C
with periodic agitation. The tumor digest was then filtered
through a 70-μm nylon filter mesh to remove undigested
tissue fragments. The resultant single tumor cell suspen-
sions were washed twice in Hank’s buffered salt solution
(HBSS) (400 g for 10 min), and viable cells were deter-
mined using trypan blue dye exclusion.
HPV16 E7-specific CD8+ T cell responses in tumor-bearing
mice treated with bortezomib and/or SAHA
Groups of C57BL/6 mice (5 per group) were challenged
with TC-1 tumor cells and treated with bortezomib and/or
SAHA as described above. To detect HPV16 E7-specific
CD8+ T cells in peripheral blood, peripheral blood mono-
nuclear cells (PBMCs) were harvested from the tail vein
one week after the last treatment. The cells were stained
with FITC-conjugated anti-mouse CD8a (BD Pharmingen,
San Diego, CA, USA) and PE-conjugated HPV16 E7
aa49-57 peptide loaded H-2Db tetramer and acquired
with FACSCalibur.
To detect HPV16 E7-specific CD8+ T cells in the tumor,
single cell suspensions were stimulated with HPV16 E7
aa49-57 peptide (1 μg/ml) in the presence of GolgiPlug
(BD Pharmingen, San Diego, CA, USA) overnight at 37°C.
The cells were then stained with PE-conjugated anti-
mouse CD8a. After permeabilization and fixation, the cells
were stained with FITC-conjugated anti-mouse IFN-γ
followed by flow cytometry analysis. The data were an-
alyzed with FlowJo or CellQuest Pro software.
IFN-γ secretion in E7-specific cytotoxic T cells induced by
bortezomib and/or SAHA pretreated TC-1 cells
2 × 105 TC-1 cells per well were plated in 6-well plates
and treated with bortezomib (3.5 nM) and/or SAHA
(12.5 μM) for 24 hours. The cells were then harvestedand 1 × 105 tumor cells per well were co-incubated with
E7-specific cytotoxic T cells in 96-well plates at 37°C for
4 hours (E:T ratio of 1:1) at the presence of GolgiPlug.
The cells were then harvested and stained with PE-
conjugated CD8 and FITC-conjugated IFN-γ. The cells
were acquired with FACSCalibur and analyzed with
FlowJo.
In vitro cytotoxic T cell assay
For the in vitro cytotoxic T cell assay, luciferase-
expressing TC-1 tumor cells were added to 96-well plates
(1 × 104 per well) and incubated overnight at 37°C. The
cells were then treated with bortezomib (3.5 nM) and/or
SAHA (12.5 μM) for 24 hours and were used as target
cells. After washing with PBS, HPV16 E7-specific cyto-
toxic T cells (CTLs), generated as previously described
[16], were added to the target cells t different E:T ratios
and incubated at 37°C for 4 hours. The target cells incu-
bated without CTLs served as a negative control. Luciferin
(1.3 × 10−4 mg per well) was added to the wells for optical
imaging. The expression of luciferase was measured using
the IVIS luminescence imaging system series 2000. Bio-
luminescence signals were acquired for 30 seconds.
Statistical analysis
All experiments were replicated twice independently. All
data were expressed as means ± standard error (SE) and
are representative of at least two independent experiments.
Otherwise indicated, the statistical significance of difference
was assessed by two-tailed Student’s t test using SPSS ver-
sion 16.0. The level of significance was set at p < 0.05.
Results
Combination treatment of bortezomib and SAHA
generates potent antitumor effects in TC-1 tumor-bearing
mice
We first characterized the antitumor effects of the pro-
teasome inhibitor bortezomib and the histone deacety-
lase inhibitor SAHA, alone or in combination against
the E7-epressing TC-1 tumor model in C57BL/6 mice.
Groups of mice were treated according to the regimens
outlined in Figure 1A. Mice were challenged with TC-1
cells and then began the various treatments five days
later. Bortezomib was injected intraperitoneally at 3 day
intervals. SAHA was administered daily from day 5 to day
14 by intraperitoneal injection. As shown in Figure 1B and
Additional file 2: Figure S2, mice treated with bortezomib
or SAHA alone had lower tumor volumes and weights
than mice treated with vehicle alone. Furthermore, mice
treated with the combination of bortezomib and SAHA
experienced significantly lower tumor volume than any
other treatment regimen. These data suggest that bortezo-
mib and SAHA elicit synergistic antitumor effects in TC-1
tumor-bearing mice.
Figure 1 In vivo tumor treatment experiments. Groups of C57BL/6 mice were subcutaneously challenged with 3 × 104 TC-1 tumor cells per
mouse on day 0. On day 5, the tumor-bearing mice were randomly divided into four groups (5 per group) and treated with one of the following
regimens: vehicle, bortezomib alone (1 mg/kg, once every 3 days), SAHA alone (30 mg/kg, once per day), or the combination of bortezomib and
SAHA. Bortezomib and SAHA were injected intraperitoneally and the treatment lasted for a total of 10 days. A. Schematic diagram of the treatment
regimens. B. Line graph depicting the tumor volume in TC-1 tumor-bearing mice treated with bortezomib and/or SAHA (mean + SE; p < 0.05).
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antigen-specific CD8+ T cells in TC-1 tumor-bearing mice
In order to characterize the antigen-specific cell-mediated
immune responses generated by bortezomib and SAHA,
groups of TC-1 tumor-bearing mice were treated as illus-
trated in Figure 1A. Splenocytes were harvested from
tumor-bearing mice one week after the last treatment and
stimulated with HPV16 E7 peptide (aa49-57). The spleno-
cytes were stained for CD8 and IFN-γ expression and ana-
lyzed by flow cytometry. As shown in Figure 2A and B, a
higher number of activated CD8+ T cells were among
splenocytes isolated from mice treated with bortezomib
and SAHA compared to those from mice treated with
bortezomib or SAHA alone. Additionally, peripheral blood
mononuclear cells (PBMCs) were harvested from the tail
vein one week after the last treatment and then stained
for CD8 expression and E7-specificity using E7 peptide-
loaded H-2Db tetramer. Mice treated with the combin-
ation of bortezomib and SAHA generated a significantly
higher percentage of E7-specific CD8+ T cells among
PBMCs compared to those treated with bortezomib or
SAHA alone (Figure 2C and D). These data suggest that,together, bortezomib and SAHA have a better ability to
generate antigen-specific CD8+ T cells than separately.
Combination treatment of bortezomib and SAHA
generates higher percentage of CD8+ T cells and
antigen-specific CD8+ T cells in the tumor
Next, we set out to characterize the immune responses
generated by bortezomib and SAHA in the tumor micro-
environment. TC-1 tumor-bearing mice were treated fol-
lowing the regimen described in Figure 1A. 4 days after
the last treatment, tumors were resected and prepared
into single tumor cells suspension by enzymatic digestion
for analyses. As shown in Figure 3A and B, treatments
with SAHA alone or SAHA in combination with bortezo-
mib induce higher numbers of CD8+ T cells in the tumor.
Furthermore, the ratios of CD8:CD4 T cells are also higher
in the tumors of mice treated with SAHA alone or SAHA
with bortezomib (Figure 3C). In addition, treatments with
SAHA alone or SAHA combined with bortezomib result
in the highest number of E7-specific IFN-γ + CD8+ T cells
in the tumors (Figure 3D and F). These data show that
treatments with SAHA alone or SAHA in combination
Figure 2 Flow cytometry analysis to determine HPV16 E7-specific CD8+ T cell responses in tumor-bearing mice treated with bortezomib
and/or SAHA. Groups of C57BL/6 mice (5 per group) were challenged with TC-1 tumor cells and treated with bortezomib and/or SAHA according
to Figure 1A. Splenocytes from tumor-bearing mice were harvested one week after the last treatment and were stimulated with HPV16 E7aa49-57
peptide (1 μg/ml). The cells were then stained with PE-conjugated anti-mouse CD8a and FITC-conjugated anti-mouse IFN-γ and analyzed by flow
cytometry. A. Bar graph depicting the number of E7-specific IFN-γ-secreting CD8+ T cells per 2 × 105 pooled splenocytes (mean + SE; p < 0.01). B.
Representative data of flow cytometry E7 peptide-loaded H-2Db tetramer staining in the various groups. C. Peripheral blood mononuclear cells (PBMCs)
were harvested from the tail vein one week after the last treatment. Cells were stained with FITC-conjugated anti-mouse CD8a and PE-conjugated
HPV16 E7aa49-57 peptide loaded H-2Db tetramer and acquired with FACSCalibur. D. Bar graph depicting the percentage of E7 tetramer CD8+ T cells
in PBMCs (p < 0.05).
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cells and higher number of antigen-specific CD8+ T cells
in the tumors. Importantly, although SAHA alone appears
to induce CD8+ T cells immune responses in the tumors,
only treatment with SAHA in combination with bortezo-
mib results in the best antitumor effects (Figure 1B).
Tumor cells treated with bortezomib and SAHA elicit
potent antigen-specific CD8+ T cell immune responses
We then treated TC-1 cells with bortezomib and/or
SAHA and subsequently incubated them with E7-specific
CD8+ T cells. Following incubation, cells were stained for
CD8 and IFN-γ expression and analyzed by flow cytome-
try. Figure 4A and B show that a significantly higher per-
centage of E7-specific CD8+ T cells incubated with TC-1
cells treated with the combination of bortezomib and
SAHA were activated, compared to those incubated withTC-1 cells treated with either bortezomib or SAHA alone.
These data suggest that tumor cells treated with the
combination of bortezomib and SAHA can activate po-
tent E7-specific CD8+ T cell immune responses.
TC-1 cells treated with the combination of bortezomib
and SAHA are rendered susceptible to CD8+ T
cell-mediated killing
In order to further elucidate the observed antitumor
effects generated by bortezomib and SAHA in tumor-
bearing mice (Figure 1), we examined the effect of bor-
tezomib and SAHA treatment on the susceptibility of
TC-1 cells to CD8+ T cell-mediated killing. Luciferase-
expressing TC-1 cells were treated with bortezomib
and/or SAHA and then incubated with E7-specific
CD8+ T cells. As shown in Figure 5A and B, E7-specific
CD8+ T cells elicited the most potent cytotoxic effect in
Figure 3 Analysis of TC-1 tumor infiltrating lymphocytes after treatment. Groups of female C57BL/6 mice (5 per group) were injected with
3 × 104 of TC-1 tumor cells subcutaneously. Five days after tumor cell injection, the mice were treated through intraperitoneal injection with one
of the following regimens: vehicle, bortezomib alone (1 mg/kg, once every 3 days), SAHA alone (30 mg/kg, once per day), or the combination of
bortezomib and SAHA as described in Figure 1A. 4 days after last treatment, the tumors were resected from the mice and the single tumor cell
suspension cells were prepared by enzymatic digestion. The cells were then stained with anti-mouse CD3, CD4 and CD8, or stimulated with
HPV16 E7aa49-57 peptide at the presence of GolgiPlug overnight followed by flow cytometry analysis A. Representative of CD3 and CD8 staining
images of TC-1 tumor single cell suspension. B. Summary of the infiltrating CD3+CD8+ T cells in TC-1 tumor. C. Summary of CD3+CD4+/CD3+CD8+ ratio
of infiltrating lymphocytes in TC-1 tumor. D. Representative of IFN-γ intracellular staining images of TC-1 tumor infiltrating CD8+ T cells. E. Summary of
IFN-γ intracellular staining data of TC-1 tumor infiltrating CD8+ T cells.
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and SAHA as demonstrated by decreased luminescence
intensity. These data suggest that bortezomib and SAHA
render TC-1 cells the most susceptible to E7-specific
CD8+ T cell-mediated killing.
Discussion
In the current study, we examined the effects of bortezo-
mib and SAHA combination treatment on host immune
responses against the TC-1 tumor model. We found that
while bortezomib and SAHA elicited antitumor effects in
TC-1 tumor-bearing mice, the combination of the two
drugs created a synergistic effect. Furthermore, we dem-
onstrated that the combination of bortezomib and SAHAgenerated significantly greater E7-specific CD8+ T cells in
the spleen and circulation compared to treatment with
either drug alone. We also showed that treatments with
SAHA alone or SAHA in combination with bortezomib
induce higher percentage of CD8+ T cells and more
antigen-specific CD8+ T cells in the tumors, however, only
the combination treatment resulted in the best antitumor
outcomes. In addition, we showed that treatment of TC-1
cells with bortezomib and SAHA led to a significant
increase in the potency of antigen-specific CD8+ T cell
immune activation. Importantly, we demonstrated that
the combination of bortezomib and SAHA rendered TC-1
cells the most susceptible to E7-specific CD8+ T cell-
mediated killing, compared to either drug alone.
Figure 4 Flow cytometry analysis to determine the ability of bortezomib and/or SAHA pretreated TC-1 cells to induce IFN-γ secretion
in E7-specific cytotoxic T cells. TC-1 cells were plated in 6-well plates (2 × 105 /well) and treated with bortezomib (3.5 nM) and/or SAHA
(12.5 μM) for 24 h. The cells were then harvested and 1 × 105 tumor cells/well were co-incubated with E7-specific CD8+ T cells in 96-well for 4 h
(E:T ratio of 1:1) in the presence of GolgiPlug. The cells were then harvested and stained with PE-conjugated CD8 and FITC-conjugated IFN-γ. Cells
were acquired with FACSCalibur and analyzed with FlowJo. A. Representative flow cytometry data demonstrating the percentage of IFN-γ positive
cells among E7-specific CTLs induced by TC-1 cells treated with bortezomib and/or SAHA. B. Bar graph depicting the percentage of IFN-γ + E7-specific
CTLs among all E7-specific CTLs induced by TC-1 cells treated with bortezomib and/or SAHA.
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therapeutic anticancer effect when TC-1 tumor-bearing
mice were treated with the combination of bortezomib
and SAHA. Our results are consistent with previously
reports of synergistic anticancer effects from the com-
bination treatment with bortezomib and SAHA in other
cancer models, such as prostate cancer [17], glioblastoma
[18], multiple myeloma [19], and T-cell lymphoma [20].
Furthermore, several clinical trials combining bortezomib
and SAHA have been reported in multiple myeloma [21],
non small-cell lung cancer [22], children with refractory
or recurrent solid tumors [23], and in patients with ad-
vanced solid tumors [24,25]. Most of these studies mainly
focus on the therapeutic effect of the combination treat-
ment rather than how it affects the host immune response
and how it renders tumor susceptible to immune-mediated
killing. Our results in cervical cancer are an important
addition to this body of literature.Here we show that treatments with either SAHA
alone or SAHA in combination with bortezomib can
induce higher percentage of CD8+ T cells and more
antigen-specific CD8+ T cells in the tumor. Although
SAHA alone appears to elicit CD8+ T cell immune re-
sponses in the tumor, only the combination treatment
generated the best antitumor outcomes (Figure 1B).
Bortezomib have been shown to enhance the immuno-
genicity in the tumor microenvironment. Importantly,
our combination treatment acts on both antigen-
specific CD8+ T cells and tumor cells. The synergistic
interaction between the potent CD8+ T cell immune
activation following SAHA treatment and the immu-
nostimulating effects of bortezomib likely contributed
to the observed potent therapeutic effect. It will be of
great interest to elucidate the precise mechanisms of
the synergistic therapeutic interactions, which warrants
further investigation.
Figure 5 In vitro cytotoxic T cell assay. Luciferase-expressing TC-1 tumor cells were added to 96-well plates (1 × 104 per well) and incubated
for 18 h at 37°C. The cells were then treated with bortezomib (3.5 nM) and/or SAHA (12.5 μM) for 24 h. After washing with PBS, HPV16 E7-specific
CTLs were added to the cells and incubated at 37°C for 4 hours. The expression of luciferase was measured using the IVIS luminescence imaging
system series 2000. Bioluminescence signals were acquired for 30 s. A. Representative luminescence images of 96-well plates showing tumor cell
lysis. B. Line graph depicting the quantification of luminescence intensity in tumor cells treated with drugs and/or E7-specific CTLs in different E:T
ratio data shown as mean ± SE.
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immunity following treatment with bortezomib and
SAHA. Our observations suggest that the combination
treatment enhances release of tumor antigen from
tumor cells, which are subsequently processed and pre-
sented by professional antigen-presenting cells (APCs).
The APCs then prime antigen-specific CD8+ T cells
through a cross-priming mechanism (for review see
[26]). Although here we only characterized E7-specific
CD8+ T cells (Figure 2), other tumor antigens were likely
released (E6, for example) promoting tumor-specific im-
munity. It is now clear the tumor-specific immunity can
contribute to antitumor effects. Thus, the tumor-specific
immunity generated through the combination treatment
of bortezomib and SAHA may contribute to the thera-
peutic antitumor effect in addition to the direct killing of
tumor cells by these chemotherapeutic drugs.
We found that tumors treated with both bortezomib
and SAHA resulted in a more potent activation of antigen-
specific CD8+ T cell immune responses (Figure 4). This
could be the result of enhanced antigen processing or
presentation through the MHC class I molecule following
the combination treatment. It will be helpful to under-
stand the precise mechanisms for such enhanced activa-
tion and should be investigated in future studies.
Interestingly, our data also show that the combination
treatment rendered tumor cells more susceptible to
antigen-specific CD8+ T cell killing (Figure 5). Taken
together, these data suggest that treatment of tumor-
bearing mice with bortezomib and SAHA will potentiallycreate potent immune-mediated therapeutic antitumor
effects through not only the enhancement of tumor-
specific immunity, but also the enhanced susceptibility of
the tumor cells to antigen-specific CD8+ T cell-mediated
killing.
Previously, our lab has used bortezomib with thera-
peutic HPV DNA vaccine for the control of TC-1 tumors
[27]. We found that the combination of CRT/E7 DNA
vaccine and bortezomib generated more potent antitumor
effects in TC-1 tumor-bearing mice compared to either
therapy alone. Considering these previous observations as
well as our current ones, we suspect that the CRT/E7
DNA vaccine could be combined with bortezomib and
SAHA in a highly potent therapy for cervical cancer.
Conclusions
Taken together, our data suggest that the host immune re-
sponse elicited by the treatment of HPV-associated tumors
with both bortezomib and SAHA represents an important
pathway contributing to the observed antitumor effects.
Both SAHA and bortezomib are commercially available for
the treatment of cutaneous T cell lymphoma and multiple
myeloma/mantle cell lymphoma, respectively. In addition,
the drug combination has been tested in some clinical trials
in patients with advanced cancer. Furthermore, the com-
bination of bortezomib and SAHA has been shown to gen-
erate synergistic killing of cervical cancer cell lines directly
[12]. Thus, the current study serves an important founda-
tion for the future clinical application of both drugs for the
treatment of cervical cancer.
Huang et al. Journal of Biomedical Science  (2015) 22:7 Page 9 of 10Additional files
Additional file 1: Figure S1. Half maximal inhibitory concentration
(IC50) of bortezomib and SAHA in TC-1 tumor cells. To determine the
viability of TC-1 cells after bortezomib and SAHA treatment, 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, 5 mg/ml) assay was
performed. TC-1 cells were plated in 96-well plates at a density of 1 × 103
cells/well and incubated at 37°C in the presence of 5% CO2 for 12 hours.
The cells were then treated with various concentrations of bortezomib or
SAHA for 48 h. At the end of the treatment period, MTS reagent was added
to each well, and the plate was incubated for 4 h at 37°C in the dark. After
incubation, the absorbance was measured at 490 nm using the VERSA Max
Microplate Reader. Data from three independent experiments were
analyzed and normalized to the absorbance of wells containing media only
(0%) and untreated cells (100%). The IC50 values were calculated from
sigmoidal dose-response curves using MS Excel software. A. Line graph
depicting the IC50 of bortezomib in the TC-1 tumor cell line. B. Line graph
depicting the IC50 of SAHA in the TC-1 tumor cell line.
Additional file 2: Figure S2. Images and weight of TC-1 tumors after
treatment. Groups of female C57BL/6 mice were injected with 3 × 104 of
TC-1 tumor cells subcutaneously. Five days after tumor cell injection, the mice
were treated through intraperitoneal injection with one of the following
regimens: vehicle, bortezomib alone (1 mg/kg, once every 3 days), SAHA
alone (30 mg/kg, once per day), or the combination of bortezomib and
SAHA as described in Figure 1A. 4 days after last treatment, the tumors
were resected from the mice and the weight of tumor was measured. A.
Images of TC-1 tumors. B. Summary of the weight of subcutaneous TC-1
tumor.
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